| A/Prof Branka Grubor Bauk |
| The University of Adelaide |
| Zika virus |
| Vaccine |
Key achievements to date:
- Industry collaboration with Vaxxas (Australia)
- Industry support from aVaxzipen (UK)
- Industry collaboration with PharmaJet (CO, USA)
- Collaboration with University of Wisconsin – Madison (WI, USA)
A/Prof Grubor-Bauk has developed an innovative, patented and thermally stable Zika virus DNA vaccine that encodes Zika virus non-structural protein 1, NS1. Extensive evaluation of this vaccine in mouse models of Zika infection has shown that it induces strong immunity and confers complete protection against systemic Zika infection. Funding from NFMRI is helping to progress the development a novel Zika virus vaccine by completing pre-clinical evaluation of this Zika virus DNA vaccine enabling Phase I Human Clinical Trials, and generating data for regulatory filing.